The entorhinal cortex (EC) serves as a critical interface between the neocortex and the hippocampal formation, playing a pivotal role in memory consolidation, spatial navigation, and executive function. In the context of neurodegenerative diseases, particularly Alzheimer's disease (AD) and Parkinson's disease (PD), the EC emerges as one of the earliest sites of pathological accumulation, making it a focal point for understanding disease progression and developing early diagnostic biomarkers. This article examines the anatomical features, connectivity patterns, and clinical significance of the entorhinal cortex in neurodegenerative disease pathogenesis. [1]
--- [2]
The entorhinal cortex is located in the medial temporal lobe, occupying the anterior portion of the parahippocampal gyrus. It lies adjacent to the hippocampus proper and extends laterally to merge with the perirhinal and parahippocampal cortices. The EC is bounded anteriorly by the amygdala and posteriorly by the parasubiculum. Anatomically, it corresponds to Brodmann areas 28 and 35, with the lateral entorhinal area (LEA) representing area 35 and the medial entorhinal area (MEA) representing area 28 1. [3]
The entorhinal cortex exhibits a characteristic six-layer cortical organization that distinguishes it from adjacent perirhinal and parahippocampal regions: [4]
The layer-specific organization of the EC is particularly relevant to neurodegenerative processes, as Layer II stellate cells demonstrate selective vulnerability to tau pathology in early AD 3. [5]
The EC is functionally and cytoarchitectonically divided into two major subdivisions: [6]
--- [7]
The entorhinal cortex houses grid cells, a population of neurons that provide a neural substrate for spatial navigation. Discovered by the Moser group in 2005, grid cells fire in a regular, hexagonal pattern that tessellates the environment, creating an internalized coordinate system 5. Grid cells are predominantly located in Layer II of the medial entorhinal cortex, where they exhibit: [8]
The grid system is thought to provide the metric component of spatial representation, interacting with place cells in the hippocampus to form a complete cognitive map 6. [9]
While place cells are primarily located in the hippocampal CA1 and CA3 regions, the entorhinal cortex provides critical input that shapes place cell firing properties. The EC receives processed spatial information from the medial septum (via GABAergic connections) and integrates this with landmark-based information from visual and olfactory cortices. Notably, experimental studies demonstrate that: [10]
Beyond spatial navigation, the EC plays a essential role in episodic memory formation. The EC serves as the "gateway" for information flow between the neocortex and hippocampus, facilitating the encoding, consolidation, and retrieval of memories. The EC is thought to: [11]
--- [12]
The Braak staging system, developed by Heiko and Eva Braak, describes the progression of neurofibrillary tau pathology in AD 8. The entorhinal cortex is affected in the earliest stages of this progression:
| Stage | Anatomical Regions Affected | Clinical Significance |
|---|---|---|
| I-II | Transentorhinal region, EC (Layers II, III) | Preclinical, subtle memory complaints |
| III-IV | Hippocampus, amygdala, basal forebrain | Mild cognitive impairment |
| V-VI | Neocortex, especially association areas | Moderate to severe dementia |
Critically, the EC shows neurofibrillary tangle (NFT) accumulation beginning at Braak stages I-II, preceding significant hippocampal involvement 9. This early involvement makes the EC a critical target for understanding preclinical AD.
The selective vulnerability of Layer II EC neurons to tau pathology has been extensively documented. These "stellate cells" demonstrate:
The transentorhinal cortex (TEC), a transitional zone between the EC and the temporal neocortex, represents the initial site of tau pathology in many cases. The TEC shows neurofibrillary changes in the absence of significant amyloid deposition, suggesting that tau pathology may initiate independently of amyloid-β 11. This finding has implications for understanding disease chronology and therapeutic targeting.
The perforant path constitutes the major white matter tract connecting the entorhinal cortex to the hippocampal formation. This pathway arises primarily from Layer II stellate cells (lateral and medial portions) and Layer III pyramidal cells, projecting to:
The perforant path is organized into two major components:
The perforant path-dentate gyrus synapse demonstrates long-term potentiation (LTP), a cellular correlate of learning and memory. Key features include:
In AD, perforant path synaptic integrity is compromised by both tau pathology and amyloid-β toxicity, contributing to memory dysfunction 13.
Structural and functional changes in the perforant path are among the earliest biomarkers of AD:
The EC receives significant cholinergic input from the basal forebrain (specifically, the medial septum and diagonal band of Broca). This cholinergic innervation is critical for:
In AD, basal forebrain cholinergic neurons degenerate early, leading to decreased cholinergic tone in the EC and hippocampus. This cholinergic deficit correlates with memory impairment and represents the basis for acetylcholinesterase inhibitor therapy 15.
The EC expresses high levels of glutamate receptors, particularly:
Excessive glutamate excitotoxicity has been implicated in EC neurodegeneration, particularly in the presence of amyloid-β and tau pathology. The EC shows increased vulnerability to excitotoxic stress due to its high density of calcium-permeable AMPA receptors 16.
Local GABAergic interneurons in the EC modulate principal cell activity and network oscillations. Several subtypes have been characterized:
GABAergic dysfunction in the EC contributes to network hyperexcitability and seizures, which are increasingly recognized as complications of AD 17.
The EC receives sparse dopaminergic input from the ventral tegmental area and noradrenergic input from the locus coeruleus. These modulatory systems influence:
Cerebrospinal fluid (CSF) biomarkers reflect molecular changes in the EC:
The combination of Amyloid-β42 (reduced) and p-tau181 (elevated) in CSF shows high sensitivity for detecting AD pathology, including early EC involvement.
Volumetric MRI shows early atrophy of the entorhinal cortex in MCI and preclinical AD:
Clinical assessment of EC function includes:
Given the early involvement of tau pathology in the EC, several tau-targeting strategies are under investigation:
Early intervention targeting EC tau may prevent downstream hippocampal dysfunction 22.
While amyloid-β deposition in the EC is less prominent than in neocortex, amyloid may contribute to EC dysfunction through:
Monoclonal antibodies targeting Aβ (lecanemab, donanemab) show modest clinical benefit in early AD, potentially through effects on synaptic protection in EC and hippocampus.
Microglial activation in the EC contributes to neurodegeneration:
While AD is the primary neurodegenerative condition affecting the EC, Parkinson's disease and related disorders also involve the EC:
In Parkinson's disease with dementia (PDD) and dementia with Lewy bodies (DLB), Lewy bodies (composed of α-synuclein) accumulate in the EC:
EC pathology in PD contributes to:
For related topics, see:
The entorhinal cortex represents a critical hub in the neural circuitry underlying memory, spatial navigation, and executive function. Its early and selective involvement in Alzheimer's disease, characterized by tau pathology beginning in Layer II, makes it a key structure for understanding disease progression and developing early diagnostic biomarkers. The EC's unique position as the gateway between the neocortex and hippocampus, combined with its role in grid cell-based spatial mapping, provides a mechanistic link between molecular pathology and clinical symptoms of neurodegeneration. Future therapeutic strategies targeting the EC—whether through anti-tau immunotherapies, neuroprotective agents, or network modulation—hold promise for intervening in the earliest stages of neurodegenerative diseases before widespread hippocampal and cortical damage occurs.
Witter MP (2007) Intrinsic and extrinsic wiring of CA3: implications for memory. Hippocampus 17:769-772. 2007. ↩︎
Palop JJ, Mucke L (2010) Synaptic depression and aberrant excitatory network activity in Alzheimer's disease. Nat Rev Neurosci 11:101-108. 2010. ↩︎
Fellgiebel A et al. (2013) Diffusion tensor imaging of the hippocampus in MCI. J Int Neuropsychol Soc 19:472-482. 2013. ↩︎
Bartus RT et al. (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408-417. 1982. ↩︎
Liu J et al. (2011) Amyloid-beta induces excitotoxicity in entorhinal cortex. Neurobiol Aging 32:2200-2209. 2011. ↩︎
Palop JJ et al. (2007) Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 55:697-711. 2007. ↩︎
Mattsson N et al. (2009) CSF biomarkers and incipient Alzheimer disease. JAMA 302:1001-1008. 2009. ↩︎
Desikan RS et al. (2009) Automated MRI measures identify MCI and AD. Neuroimage 47:114-124. 2009. ↩︎
Schwarz AJ et al. (2018) Topographic distribution of tau in vivo using flortaucipir PET. J Nucl Med 59:1383-1390. 2018. ↩︎
Ji Y et al. (2017) Free-water imaging of the entorhinal cortex in early AD. Neuroimage Clin 15:558-565. 2017. ↩︎
Lee G et al. (2019) Tau-directed therapies: opportunities and challenges. Nat Rev Neurol 15:9-22. 2019. ↩︎
Olson ML et al. (2017) CSF1R inhibition reduces microglia, promotes oligodendrogenesis. Glia 65:1094-1106. 2017. ↩︎